Two different preparation questions
Bowel-cleansing quality and sedation safety should not be treated as the same issue
A colonoscopy requires adequate cleansing of the colon so the endoscopist can inspect the lining. If moderate sedation, deep sedation, or general anesthesia is planned, the team may also consider delayed stomach emptying and retained gastric contents. GLP-1 medicines can affect gastrointestinal motility, but a clean colon does not prove an empty stomach, and standard fasting does not prove that the bowel preparation will be adequate. The gastroenterology, anesthesia, diabetes, and prescribing plans therefore need to be coordinated rather than reduced to one online stop date.
- Ask which team owns the GLP-1 decision, the bowel-prep prescription, fasting instructions, glucose plan, and restart decision.
- Tell the team whether the colonoscopy uses no sedation, moderate sedation, deep sedation, or general anesthesia and whether an upper endoscopy is planned at the same visit.
- Do not add laxatives, extend fasting, change clear-liquid intake, or cancel a prescribed medicine without instructions for your health history and procedure.
Current bowel-prep evidence
Studies report an association with inadequate preparation—not a universal outcome or self-treatment rule
A 2025 systematic review and meta-analysis included five studies and 10,833 patients. It reported higher odds of inadequate bowel preparation among GLP-1 receptor-agonist users than controls (odds ratio 2.10, 95% confidence interval 1.41 to 3.13). A large matched regional cohort published in a 2026 journal issue compared 503 GLP-1 users with 503 matched controls and reported more composite inadequate-prep outcomes (125 versus 56; odds ratio 2.6, 95% confidence interval 1.9 to 3.7) and more repeat procedures (26 versus 9; odds ratio 3.0, 95% confidence interval 1.4 to 6.5). These group-level findings are important planning signals, but much of the evidence is observational and cannot predict one patient or establish that withholding a GLP-1, using a longer fast, or changing a bowel prep will prevent failure.
- Keep the published numbers tied to the studied cohorts; do not present them as a personal probability or as proof that the medicine caused one inadequate prep.
- Report a prior poor prep, chronic constipation, slow-transit or motility disorder, diabetes, opioid or anticholinergic use, kidney or heart disease, dehydration risk, and difficulty completing a previous prep.
- Ask whether the endoscopy unit has a current GLP-1-specific protocol and who should modify the prescribed bowel-prep plan when individual risk is higher.
Current peri-procedure guidance
Risk factors and shared decisions matter more than a copied hold interval
The multi-society perioperative guidance represented gastroenterology, anesthesia, metabolic and bariatric surgery, obesity perioperative care, and gastrointestinal endoscopic surgery groups. It recommends shared decision-making that balances delayed-emptying risk against the medical and metabolic risks of withholding therapy. Factors that can raise concern include being in dose escalation, a higher dose, a weekly formulation, active gastrointestinal symptoms, or another condition that slows gastric emptying. When concern is elevated, the clinical team may consider measures such as a pre-procedure liquid diet, anesthesia-plan changes, selected point-of-care gastric ultrasound, or postponement. Those are clinician decisions; the guidance says the duration to hold therapy is unknown when a hold is chosen.
- Do not assume the old “daily medicine for one day, weekly medicine for one week” approach remains the universal rule for every colonoscopy.
- Tell the team promptly about nausea, vomiting, reflux, bloating, abdominal pain, constipation, poor intake, dehydration, gastroparesis, or a recent dose increase.
- Urgent procedures and unexpected symptoms need direct procedure-team management rather than waiting for an online schedule to fit.
Exact product, route, and indication
Daily tablets, weekly injections, branded products, and compounded preparations require accurate identification
Current official records include injection and tablet presentations within the Wegovy label set, and current Ozempic records also require presentation-specific review rather than defining the entire brand as injection-only. Mounjaro and Zepbound are tirzepatide injections with separate manufacturer labels and indication contexts. A patient-specific compounded semaglutide or tirzepatide preparation is not an FDA-approved finished drug product and may use a different concentration, container, label, storage instruction, or ingredient combination. The procedure team should see the actual package or pharmacy label rather than infer timing from a brand nickname.
- Share the active ingredient, brand, route, presentation, prescribing instructions, last-use time, treatment reason, dose-escalation status, prescriber, and dispensing pharmacy.
- List insulin, sulfonylureas, metformin, SGLT2 inhibitors, other diabetes medicines, opioids, anticholinergics, constipation medicines, supplements, and every product that could affect glucose, hydration, or motility.
- Reject no-prescription GLP-1s, “generic” brand claims, research-use vials, copied syringe conversions, pen-click charts, and compounded products marketed as FDA approved.
Procedure-day and restart planning
A delayed, canceled, or incomplete colonoscopy needs a coordinated next step
Call the endoscopy unit if the written medication plan is missing, instructions from different clinicians conflict, the prep cannot be completed, stool output does not match the unit’s instructions, vomiting prevents fluid intake, new abdominal symptoms develop, or glucose is outside the threshold the diabetes team provided. If the procedure is delayed or canceled, do not automatically repeat bowel-prep products or resume, skip, double, split, or make up GLP-1 doses. Restart timing can depend on the exact product and route, oral intake, hydration, glucose, gastrointestinal symptoms, missed-dose labeling, procedure findings, and clinician plan.
- Obtain written instructions before the prep begins whenever possible, especially during dose escalation or after a previous inadequate preparation.
- Ask what to do with each diabetes medicine during reduced intake and bowel prep; do not treat a GLP-1 plan as a complete glucose-management plan.
- Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, severe weakness, breathing trouble, or serious low- or high-glucose symptoms needs prompt medical assessment.